DE602005011132D1 - Neuartige cis-imidazoline - Google Patents

Neuartige cis-imidazoline

Info

Publication number
DE602005011132D1
DE602005011132D1 DE602005011132T DE602005011132T DE602005011132D1 DE 602005011132 D1 DE602005011132 D1 DE 602005011132D1 DE 602005011132 T DE602005011132 T DE 602005011132T DE 602005011132 T DE602005011132 T DE 602005011132T DE 602005011132 D1 DE602005011132 D1 DE 602005011132D1
Authority
DE
Germany
Prior art keywords
novel cis
imidazoline
cis imidazoline
novel
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005011132T
Other languages
English (en)
Inventor
Nader Fotouhi
Gregory Jay Haley
Klaus B Simonsen
Binh Thanh Vu
Stephen Evan Webber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602005011132D1 publication Critical patent/DE602005011132D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26Radicals substituted by carbon atoms having three bonds to hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602005011132T 2004-05-18 2005-05-10 Neuartige cis-imidazoline Active DE602005011132D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57227504P 2004-05-18 2004-05-18
US61553404P 2004-10-01 2004-10-01
US66877205P 2005-04-06 2005-04-06
PCT/EP2005/005046 WO2005110996A1 (en) 2004-05-18 2005-05-10 Novel cis-imidazolines

Publications (1)

Publication Number Publication Date
DE602005011132D1 true DE602005011132D1 (de) 2009-01-02

Family

ID=35058746

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005011132T Active DE602005011132D1 (de) 2004-05-18 2005-05-10 Neuartige cis-imidazoline

Country Status (21)

Country Link
US (2) US7964724B2 (de)
EP (1) EP1753727B1 (de)
JP (1) JP4814228B2 (de)
KR (3) KR20080027969A (de)
CN (1) CN1953965B (de)
AR (1) AR049545A1 (de)
AT (1) ATE414693T1 (de)
AU (1) AU2005243465B2 (de)
BR (1) BRPI0511328A (de)
CA (1) CA2565189A1 (de)
DE (1) DE602005011132D1 (de)
ES (1) ES2314660T3 (de)
IL (1) IL178884A (de)
MX (1) MXPA06013246A (de)
MY (1) MY143800A (de)
NO (1) NO20065730L (de)
PE (1) PE20060679A1 (de)
RU (1) RU2006144811A (de)
TW (1) TW200600501A (de)
WO (1) WO2005110996A1 (de)
ZA (1) ZA200609595B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
RU2411238C2 (ru) 2005-03-16 2011-02-10 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-триарилимидазолины и их применение в качестве противораковых лекарственных средств
CN101316823B (zh) 2005-12-01 2013-05-22 霍夫曼-拉罗奇有限公司 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物
KR101015073B1 (ko) * 2006-01-18 2011-02-16 에프. 호프만-라 로슈 아게 Mdm2 억제제로서의시스-4,5-비아릴-2-헤테로시클릭-이미다졸린
JP2009542666A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション P53活性を増加させる置換ピペリジンおよびその使用
BRPI0719345A2 (pt) * 2006-11-27 2014-03-18 Novartis Ag Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
EP2103619A4 (de) 2006-12-14 2011-11-23 Daiichi Sankyo Co Ltd Imidazothiazolderivate
CA2939778C (en) * 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
BRPI0817850A2 (pt) 2007-10-09 2015-04-07 Hoffmann La Rouche Ag F Cis-imidazolinas quirais
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 4,7−ジアザスピロ[2.5]オクタン環構造を有するイミダゾチアゾール誘導体
DE102008047128A1 (de) * 2008-09-15 2010-04-15 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von cis-Imidazolinen, insbesondere Nutlinen, zur Behandlung von chemoresistenten Krebserkrankungen
MX2011007598A (es) 2009-01-16 2011-08-08 Daiichi Sankyo Co Ltd Derivados de imidazotiazol que tienen estructura de anillo de prolina.
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
JP2013510860A (ja) 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールmdm2アンタゴニスト
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
US9266860B2 (en) 2010-09-30 2016-02-23 St. Jude Children's Research Hospital Aryl-substituted imidazoles
AU2011326395B2 (en) 2010-11-12 2016-01-07 Ascenta Licensing Corporation Spiro-oxindole MDM2 antagonists
SI2684880T1 (en) 2011-03-10 2018-08-31 Daiichi Sankyo Company, Limited DERIVAT DISPIROPYROLIDINE
AU2012253339B2 (en) 2011-05-11 2016-03-31 Sanofi Spiro-oxindole MDM2 antagonists
JP6093770B2 (ja) 2011-09-27 2017-03-08 アムジエン・インコーポレーテツド 癌の治療のためのmdm2阻害剤としての複素環化合物
WO2013054153A1 (en) 2011-10-11 2013-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Nutlin compounds for use in he treatment of pulmonary hypertension
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
US8987274B2 (en) 2011-10-28 2015-03-24 Merck Sharp & Dohme Corp Macrocycles that increase p53 activity and the uses thereof
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104159595A (zh) 2012-02-15 2014-11-19 爱勒让治疗公司 拟肽大环化合物
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
EP2951180B1 (de) * 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8-substituierte purine als hdm2-inhibitoren
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2961735B1 (de) 2013-02-28 2017-09-27 Amgen Inc. Von der benzoesäure abgeleiteter mdm2-hemmer zur behandlung von krebs
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
AU2014272774B2 (en) 2013-05-27 2016-12-08 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease
US9624247B2 (en) 2013-05-28 2017-04-18 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
PT3004112T (pt) 2013-05-28 2017-12-11 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona e sua utilização no tratamento de doença
CN104208066B (zh) * 2013-06-03 2016-06-15 中国科学院遗传与发育生物学研究所 哌嗪衍生物作为p53分子调节剂的用途
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
MX2016006667A (es) 2013-11-21 2016-07-26 Novartis Ag Derivados de pirrolo-pirrolona y su uso como inhibidores.
WO2016049355A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
RS58961B1 (sr) 2015-01-22 2019-08-30 Sanofi Aventis Deutschland Proces proizvodnje 2-[4-(ciklopropankarbonil)fenil]-2-metil-propannitrila
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3347372A4 (de) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. Peptidomimetische makrocyclen als modulatoren von mcl-1
BR112018070549A2 (pt) 2016-04-06 2019-02-12 The Regents Of The University Of Michigan degradantes de proteína mdm2
EP3440082A1 (de) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunktionelle zwischenprodukte für den ligandenabhängigen zielproteinabbau
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
US20210198223A1 (en) * 2017-10-20 2021-07-01 Corbus Pharmaceuticals, Inc. Methods and compositions relating to ultrapure 5-(1,1-dimethylheptyl)-resorcinol
WO2020076660A1 (en) 2018-10-08 2020-04-16 The Regents Of The University Of Michigan Small molecule mdm2 protein degraders
CN115776887A (zh) 2020-03-19 2023-03-10 凯麦拉医疗公司 Mdm2降解剂和其用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11504381B1 (en) * 2021-11-22 2022-11-22 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
US11548866B1 (en) 2021-11-22 2023-01-10 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
KR20230087856A (ko) 2021-12-10 2023-06-19 교촌 에프 앤 비(주) 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
DE4203547A1 (de) * 1992-02-07 1993-08-12 Knoll Ag Verfahren zur racemattrennung von verapamil
FR2756560A1 (fr) * 1996-12-04 1998-06-05 Adir Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
US6653501B2 (en) * 2001-06-27 2003-11-25 Napro Biotherapeutics, Inc. Chiral resolution method for producing compounds useful in the synthesis of taxanes
EP1458380B1 (de) * 2001-12-18 2008-03-19 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
JP4361798B2 (ja) * 2001-12-18 2009-11-11 エフ.ホフマン−ラ ロシュ アーゲー Mdm2インヒビターとしてのシス−イミダゾリン

Also Published As

Publication number Publication date
CA2565189A1 (en) 2005-11-24
WO2005110996A1 (en) 2005-11-24
ZA200609595B (en) 2008-06-25
BRPI0511328A (pt) 2007-12-04
CN1953965A (zh) 2007-04-25
RU2006144811A (ru) 2008-06-27
KR20110033964A (ko) 2011-04-01
KR20070011516A (ko) 2007-01-24
JP2007538022A (ja) 2007-12-27
TW200600501A (en) 2006-01-01
US20090143364A1 (en) 2009-06-04
US7964724B2 (en) 2011-06-21
EP1753727B1 (de) 2008-11-19
ES2314660T3 (es) 2009-03-16
PE20060679A1 (es) 2006-08-11
EP1753727A1 (de) 2007-02-21
CN1953965B (zh) 2012-07-04
NO20065730L (no) 2007-01-19
IL178884A0 (en) 2007-03-08
MXPA06013246A (es) 2007-02-08
US20050288287A1 (en) 2005-12-29
AU2005243465A1 (en) 2005-11-24
KR100832277B1 (ko) 2008-05-26
AU2005243465B2 (en) 2011-08-25
JP4814228B2 (ja) 2011-11-16
IL178884A (en) 2010-12-30
ATE414693T1 (de) 2008-12-15
MY143800A (en) 2011-07-15
AR049545A1 (es) 2006-08-16
KR20080027969A (ko) 2008-03-28

Similar Documents

Publication Publication Date Title
DE602005011132D1 (de) Neuartige cis-imidazoline
CY2019034I2 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
DE112005001624A5 (de) Brillengestell
ATE392425T1 (de) Thiazolyl-dihydro-indazole
ATE459633T1 (de) Makrolide
DE502005004843D1 (de) Einspritzventil
DE502005004842D1 (de) Wischblatt
DE112005000809A5 (de) Wankstabilisierungseinrichtung
DE602005012491D1 (de) Zentrifugaldruckpumpe
DE602005027311D1 (de) Empfänger
DE502005002602D1 (de) Fahrzeugtemperiersystem
ATE521769T1 (de) Beschlag
DE502005004695D1 (de) Sicherheitsfangseil
AT500198B1 (de) Ladewagen
DE202004017327U1 (de) Fitnessrad
ATE389633T1 (de) Omega-phenyloctanamide
DE112005000794T5 (de) Urethanspritzpistolenanordnung
DE502005004160D1 (de) Seitenblinkleuchte
AT500249A3 (de) Scheibenegge
DE502005003159D1 (de) Kettenstichnähvorrichtung
DE502004001961D1 (de) Barikadenbrecher
DE112005002245A5 (de) Polymerdichtung
DE112005001019A5 (de) Kunststoffschraubverschlusskappe
DE502004006251D1 (de) Holzentrindungsanlage
ATA9982004A (de) Tiefbohrbrunnen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition